Abstract 1251P
Background
Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).
Methods
NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).
Results
Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P
Patients characteristics
| Cohort A patients (%) 96 | Cohort B patients (%) 94 | |
| Sex MF | 62 (64.5%)34 (35.5%) | 66 (70%)28 (30%) |
| Smoke YesNo | 85 (88%)9 (12%) | 85 (90%)9 (10%) |
| Age years MedianRange | 68 y44-83 | 66 y42-84 |
| Histology AdenocarcinomaSquamocellularOthers | 54 (56%)39 (41%)3 (3%) | 49 (52%)39 (41%)6 (7%) |
| PD-L1 expression 01-49≥ 50Not tested | 12 (12.5%)41 (43%)30 (31%)13 (13.5%) | 11 (12%)15 (16%)9 (10%)59 (62%) |
| Stage disease IIIAIIIBIIIC | 35 (36.5%)48 (50%)13 (13.5%) | 39 (41%)44 (47%)11 (12%) |
| ECOG PS 012 | 59 (61.5%)35 (37.5%)1 (1%) | 60 (64%)34 (36%)0 |
Conclusions
Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.
Clinical trial identification
ESR-19-20410.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1271P - Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC
Presenter: Hakan Bozcuk
Session: Poster session 05
1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 05
Resources:
Abstract
1274P - Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 05
1276P - EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status
Presenter: Chiara Bennati
Session: Poster session 05
1277P - Optimising targeted therapy in NSCLC: A comprehensive analysis of oncogenic fusion mutations and co-mutation landscapes
Presenter: Li Dongge
Session: Poster session 05
1278P - Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Presenter: Yuan-Kai Shi
Session: Poster session 05
1279P - First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
Presenter: Yi-Long Wu
Session: Poster session 05
1280P - Effects of semaglutide on the exposure of alectinib in patients with NSCLC
Presenter: Daan Lanser
Session: Poster session 05
1281P - Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
Presenter: Niels Heersche
Session: Poster session 05